Europe - Germany • Industry focus
Taylor Wessing
Taylor Wessing's focus is mirrored in the practice group management: Anja Lunze heads the life sciences segment, while Michael Stein is the key contact for the healthcare sector. Clients benefit from the close cooperation of the corporate, M&A and regulatory teams, where the team regularly supports buyers in transactions in the outpatient and inpatient sectors and in the formation of groups of medical care centers; the team also covers the procurement law interface, including advising hospital chains on the Hospital Future Act and the implementation of IT system, above all, hospital information systems. The focus in the life sciences area is on advising pharmaceutical and biotechnology companies on medical, pharmaceutical, patent and trademark law issues, including product liability and contentious matters. This is completed by capacities in the digital healthcare segment, where the regulatory team frequently cooperates with the TMT practice. Medical law expert Karolina Lange-Kulmann was appointed partner in April 2023, while Stefanie Greifeneder (regulatory, commercial and contract-related matters in the pharmaceutical, medical device and biotechnology sectors; compliance) joined the team the following month from Fieldfisher.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'The Taylor Wessing team has always been very responsive, well prepared and extremely professional.'
- 'Collaboration is always fair and based on transparency and a high level of accuracy.'
- 'We are impressed by the team's integrated approach and deep industry know-how. Inquiries are answered quickly, competently and practically. The understanding of the problem, shaped by years of industry experience, and the creativity in problem solving are convincing.'
- 'The practice has an extremely high level of competence in all areas. This means that complex issues that do not just affect one regulatory area are dealt with in an interdisciplinary and holistic manner.'
- 'Daniel Tietjen has excellent knowledge of competition law, particularly pharmaceutical advertising law, and regularly supports us in this area. I really appreciate the practical but also creative solutions.'
- 'The team offers uncomplicated, expert support at all times.'
- 'Daniel Tietjen always responds quickly, works very conscientiously and is always very solution-oriented.'
- 'Hands-on and strong in teamwork on interdisciplinary cases.'
Key clients
- Amedes
- AstraZeneca
- Azenta INC
- Bayer
- Cochlear
- Daiichi Sankyo
- Dana-Faber Cancer Institute
- Fresenius Kabi Swiss BioSim
- Morphosys
- MTK Pharma
- NORD Holding
- Oberberg
- Pfizer
- Sanecum
- STADA Arzneimittel
- Viatris
Work highlights
- Advising numerous financial investors and their portfolio companies (including amedes, NORD Holding, Oberberg, Sanecum and Trilantic) on various transactions in the inpatient and outpatient sectors, particularly with regard to the implementation of their respective buy-and-build strategies.
- Defending AstraZeneca against consumer lawsuits regarding its Covid-19 vaccine.
- Representing Pfizer in the patent infringement proceedings brought by Moderna regarding the alleged infringement of mRNA vaccine patents (Comirnaty).
Practice head
The lawyer(s) leading their teams.
Anja Lunze, Michael Stein